Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1 1

Status

Completed 33Terminated 11Unknown 3Recruiting 3Active not recruiting 3

Sponsor Class

NIH 1NETWORK 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3CNS 1

Conditions

Prostatic Neoplasms 25Breast Neoplasms 21Glioblastoma 19Carcinoma, Non-Small-Cell Lung 17Sarcoma 11Squamous Cell Carcinoma of Head and Neck 10Lung Neoplasms 10Rectal Neoplasms 8Neoplasms 8Hodgkin Disease 8Head and Neck Neoplasms 8Brain Neoplasms 8Oropharyngeal Neoplasms 7Glioma 7Esophageal Squamous Cell Carcinoma 7Esophageal Neoplasms 7Uterine Cervical Neoplasms 6Pancreatic Neoplasms 6Astrocytoma 6Triple Negative Breast Neoplasms 5Lymphoma 5Colorectal Neoplasms 5Carcinoma, Squamous Cell 5Neoplasm Metastasis 4Melanoma 4Medulloblastoma 4Histiocytoma, Malignant Fibrous 4Small Cell Lung Carcinoma 3Rhabdomyosarcoma 3Recurrence 3

Interventions

Oxaliplatin 7Fluorouracil 7Leucovorin 6pembrolizumab 4Paclitaxel 4Capecitabine 4Radiotherapy 3Radiation 3Nivolumab 3Cisplatin 3zimberelimab 2tislelizumab 2durvalumab 2Trastuzumab 2Taxes 2Levoleucovorin 2Irinotecan 2zanidatamab 1tucatinib 1trifluridine tipiracil drug combination 1tremelimumab 1trastuzumab deruxtecan 1spartalizumab 1quemliclustat 1obinutuzumab 1naptumomab estafenatox 1lenvatinib 1futibatinib 1dehydroftorafur 1cixutumumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Active not recruiting × Adenocarcinoma Of Esophagus × Radiotherapy × Clear all
NCT04210115 2026-05-13

KEYNOTE 975

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting
703 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma

NCT04248452 2026-05-05

Testing the Addition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients With Esophageal and Gastric Cancer That Has Spread to a Limited Number of Other Places in the Body

Eastern Cooperative Oncology Group

Phase 3 Active not recruiting
314 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus

NCT04460937 2026-04-29

Testing the Addition of an Anti-cancer Drug, Adavosertib, to Radiation Therapy for Patients With Incurable Esophageal and Gastroesophageal Junction Cancers

National Cancer Institute (NCI)

Phase 1 Active not recruiting
4 enrolled 9 charts
CNSGastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Brain Neoplasms, Meningeal Carcinomatosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡